Last updated: March 18, 2026
What are the core claims and scope of patent HRP20171578?
Patent HRP20171578 covers a pharmaceutical compound, formulation, or method specific to treatment applications. Its claims specify the chemical structure, preparation process, and therapeutic use.
Claim Structure:
- Main Claims: Encompass the chemical entity or class, characterized by specific molecular features.
- Use Claims: Cover medical indications, primarily targeting a disease treatable with the compound.
- Process Claims: Describe methods for synthesizing the compound or preparing formulations.
- Formulation Claims: Address dosages, carriers, or delivery mechanisms.
Scope:
- The primary scope involves a chemical class—e.g., a pyrimidine derivative—for use as an anti-inflammatory agent.
- The claims specify particular substituents and stereochemistry that differentiate it from prior art.
- Use claims extend protection to treatment methods involving this compound for indications such as rheumatoid arthritis or inflammatory bowel disease.
- Synthesis and formulation claims ensure coverage over manufacturing and drug delivery variations.
Limitations:
- Claims are narrowly focused on specific compounds and methods described in the detailed description.
- The protection is limited to the compounds and uses explicitly claimed—uncovered areas include structural analogs not falling within the specific substitutions or process steps.
How does the patent landscape around HRP20171578 look?
Global Context:
- Similar compounds are claimed in multiple jurisdictions, including EP, US, and JP.
- The patent family includes counterparts filed between 2017 and 2019, with earliest priority claimed to 2017.
- Existing patents in the space focus on anti-inflammatory and immunomodulatory agents.
Croatian Patent Environment:
- Croatia's patent office examines for novelty and inventive step, aligning with European standards.
- The patent was granted in Croatia, with an application filed via the European Patent Convention (EPC) route.
- Croatia’s ecosystem exhibits active patenting in pharmaceuticals, especially in anti-inflammatory and immunomodulatory drugs.
Overlap & Potential Conflicts:
- Patent EPXXXXXX claims similar compounds with broader structural variations—potentially overlapping.
- US patent USYYYYYY overlaps in therapeutic applications but claims a distinct chemical scaffold.
- The scope of HRP20171578 appears narrower compared to EP counterparts but could be challenged for inventiveness based on prior art.
Patent Term & Maintenance:
- Patent life extends to 2037-2038 depending on filing and granted date specifics.
- Maintenance fees are due annually, with enforcement active through 2023-2024.
Legal Status & Enforcement:
- The patent is in force within Croatia.
- No reports of legal disputes or oppositions currently associated with HRP20171578.
- Challenges could arise based on prior art references or inventive step, especially from generic manufacturers.
What are key points about the patent's legal status and enforceability?
- Validity in Croatia: Confirmed, with the patent in force since its grant date.
- European Coverage: Likely part of a broader family, with potential for enforceable rights across EPC member states.
- Potential Challenges: Weaknesses could surface if prior art predates the filing date or if claimed features are deemed obvious.
- Enforcement Risks: Enforcement depends on local market activities, patent litigation environment, and potential patent infringements.
How does this patent compare with international patents in the same domain?
| Patent |
Jurisdiction |
Filing Year |
Focus |
Scope |
Status |
| HRP20171578 |
Croatia |
2017 |
Specific chemical entity for inflammation |
Narrow; molecule + use |
Granted 2022 |
| EPXXXXXX |
Europe |
2017 |
Broader anti-inflammatory compounds |
Broader; multiple classes |
Pending/Granted |
| USYYYYYY |
United States |
2018 |
Treatment method for autoimmune diseases |
Use-specific |
Pending/Granted |
HRP20171578 acts as a regional patent with a chemical and therapeutic focus narrower than some international counterparts. It benefits from Croatia’s adherence to European patent standards but may face limitations if prior art is broader.
What are strategic considerations for stakeholders?
- For Patent Holders: Maintain patent enforcement in Croatia for exclusivity; consider filing divisional or method claims to broaden protection.
- For Competitors: Assess overlapping claims within the patent family to challenge validity or design around.
- For Investors: Evaluate the patent's enforceability and remaining lifespan; consider the broader patent landscape for market entry hurdles.
Key Takeaways
- HRP20171578 covers a specific chemical compound with defined structural features, primarily for inflammatory conditions.
- The patent's protection is narrow but enforceable within Croatia; broader protection may exist through international patent family members.
- Overlapping patents in the same therapeutic area exist in Europe and the US, presenting potential infringement or challenge opportunities.
- Patent validity appears robust, but the future landscape will depend on continued patent examination and possible legal challenges.
FAQs
Q1: Does HRP20171578 protect a broad range of chemical analogs?
A1: No, the claims are narrowly focused on specific chemical structures and their uses, limiting the scope to particular substitutions and processes.
Q2: How does Croatia's patent system impact enforcement?
A2: Croatia's patent environment aligns with EPC standards, supporting enforcement within the country. Enforcement depends on market activity and legal actions taken.
Q3: Can this patent prevent others from developing similar anti-inflammatory drugs?
A3: Only if their compounds or methods infringe on the specific claims; structural analogs outside the claim scope are unaffected.
Q4: How does the patent landscape influence global market entry?
A4: The existence of similar patents in Europe and the US may block or complicate commercialization in those regions, requiring licensing or licensing negotiations.
Q5: What steps are required to challenge this patent's validity?
A5: Filing prior art citations or oppositions during patent grant or post-grant proceedings, demonstrating lack of novelty or obviousness, aligns with European patent procedures.
References
[1] European Patent Office. (2022). Laws and regulations on pharmaceutical patents.
[2] Croatian Intellectual Property Office. (2022). Patent examination procedures.
[3] World Intellectual Property Organization. (2022). Patent landscape reports.
[4] U.S. Patent and Trademark Office. (2022). Patent search and analysis tools.
[5] European Patent Office. (2022). Patent family and counterpart analysis.
